264 related articles for article (PubMed ID: 20021336)
1. Recent advances in the treatment of amyotrophic lateral sclerosis. Emphasis on kynurenine pathway inhibitors.
Chen Y; Meininger V; Guillemin GJ
Cent Nerv Syst Agents Med Chem; 2009 Mar; 9(1):32-9. PubMed ID: 20021336
[TBL] [Abstract][Full Text] [Related]
2. Involvement of quinolinic acid in the neuropathogenesis of amyotrophic lateral sclerosis.
Lee JM; Tan V; Lovejoy D; Braidy N; Rowe DB; Brew BJ; Guillemin GJ
Neuropharmacology; 2017 Jan; 112(Pt B):346-364. PubMed ID: 27265569
[TBL] [Abstract][Full Text] [Related]
3. Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis.
Guillemin GJ; Meininger V; Brew BJ
Neurodegener Dis; 2005; 2(3-4):166-76. PubMed ID: 16909022
[TBL] [Abstract][Full Text] [Related]
4. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Tan L; Yu JT; Tan L
J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the kynurenine pathway in NSC-34 cell line: implications for amyotrophic lateral sclerosis.
Chen Y; Brew BJ; Guillemin GJ
J Neurochem; 2011 Sep; 118(5):816-25. PubMed ID: 21182524
[TBL] [Abstract][Full Text] [Related]
6. The kynurenine pathway and inflammation in amyotrophic lateral sclerosis.
Chen Y; Stankovic R; Cullen KM; Meininger V; Garner B; Coggan S; Grant R; Brew BJ; Guillemin GJ
Neurotox Res; 2010 Aug; 18(2):132-42. PubMed ID: 19921535
[TBL] [Abstract][Full Text] [Related]
7. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities.
Schwarcz R; Pellicciari R
J Pharmacol Exp Ther; 2002 Oct; 303(1):1-10. PubMed ID: 12235226
[TBL] [Abstract][Full Text] [Related]
8. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.
Heyes MP; Saito K; Crowley JS; Davis LE; Demitrack MA; Der M; Dilling LA; Elia J; Kruesi MJ; Lackner A
Brain; 1992 Oct; 115 ( Pt 5)():1249-73. PubMed ID: 1422788
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia.
Notarangelo FM; Wilson EH; Horning KJ; Thomas MA; Harris TH; Fang Q; Hunter CA; Schwarcz R
Schizophr Res; 2014 Jan; 152(1):261-7. PubMed ID: 24345671
[TBL] [Abstract][Full Text] [Related]
10. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
Heyes MP; Saito K; Major EO; Milstien S; Markey SP; Vickers JH
Brain; 1993 Dec; 116 ( Pt 6)():1425-50. PubMed ID: 8293279
[TBL] [Abstract][Full Text] [Related]
11. Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Mohamadkhani A; Klegeris A; McElhinney A; Mafi Z; Hajiesmaeili M; Sayehmiri F
Front Immunol; 2022; 13():1013784. PubMed ID: 36426364
[TBL] [Abstract][Full Text] [Related]
12. Kynurenic acid antagonists and kynurenine pathway inhibitors.
Stone TW
Expert Opin Investig Drugs; 2001 Apr; 10(4):633-45. PubMed ID: 11281814
[TBL] [Abstract][Full Text] [Related]
13. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences.
Fujigaki H; Yamamoto Y; Saito K
Neuropharmacology; 2017 Jan; 112(Pt B):264-274. PubMed ID: 26767951
[TBL] [Abstract][Full Text] [Related]
14. Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases.
Lovelace MD; Varney B; Sundaram G; Lennon MJ; Lim CK; Jacobs K; Guillemin GJ; Brew BJ
Neuropharmacology; 2017 Jan; 112(Pt B):373-388. PubMed ID: 26995730
[TBL] [Abstract][Full Text] [Related]
15. Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications.
Ceresoli-Borroni G; Guidetti P; Amori L; Pellicciari R; Schwarcz R
J Neurosci Res; 2007 Mar; 85(4):845-54. PubMed ID: 17279543
[TBL] [Abstract][Full Text] [Related]
16. Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms.
Castellano-Gonzalez G; Jacobs KR; Don E; Cole NJ; Adams S; Lim CK; Lovejoy DB; Guillemin GJ
Neurotox Res; 2019 Apr; 35(3):530-541. PubMed ID: 30666558
[TBL] [Abstract][Full Text] [Related]
17. Hypothesis kynurenic and quinolinic acids: The main players of the kynurenine pathway and opponents in inflammatory disease.
Badawy AA
Med Hypotheses; 2018 Sep; 118():129-138. PubMed ID: 30037600
[TBL] [Abstract][Full Text] [Related]
18. Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse.
Saito K; Markey SP; Heyes MP
Neuroscience; 1992 Nov; 51(1):25-39. PubMed ID: 1465184
[TBL] [Abstract][Full Text] [Related]
19. Peripheral and central kynurenine pathway abnormalities in major depression.
Paul ER; Schwieler L; Erhardt S; Boda S; Trepci A; Kämpe R; Asratian A; Holm L; Yngve A; Dantzer R; Heilig M; Hamilton JP; Samuelsson M
Brain Behav Immun; 2022 Mar; 101():136-145. PubMed ID: 34999196
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of [5-(3)H]kynurenine in the developing rat brain in vivo: effect of intrastriatal ibotenate injections.
Ceresoli G; Guidetti P; Schwarcz R
Brain Res Dev Brain Res; 1997 May; 100(1):73-81. PubMed ID: 9174248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
